Dose Insider / Outsourcing pharmacies / F.H. Investments, Inc.

F.H. Investments, Inc.FDA registration and inspection record

FDA list of November 17, 2026 · checked against fda.gov on November 20, 2026

F.H. Investments, Inc. in Birmingham, Alabama is registered with FDA as a 503B outsourcing facility, first on May 13, 2025 and most recently on December 2, 2025. FDA last inspected it on December 19, 2025 and issued a Form 483 with 10 observations.

10 observationsin the Form 483 of FDA’s inspection on December 19, 2025
Observations in the last Form 483FDA inspection reports of registered outsourcing facilitiesF.H. Investments, Inc.10Median facility5Most in one report16Observations in the lastForm 483FDA inspection reports of registered outsourcingfacilitiesF.H. Investments, Inc.10Median facility5Most in one report16

F.H. Investments, Inc. had more observations than the median inspected facility.

On this page

These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.

What does FDA’s record show, in brief?

FacilityF.H. Investments, Inc.
LocationBirmingham, Alabama
Type503B outsourcing facility
Registered sinceMay 13, 2025
Latest registrationDecember 2, 2025
Last FDA inspectionDecember 19, 2025
Inspection dates12/05/2025 to 12/19/2025
Form 483Issued, 10 observations
FDA action after the inspectionOpen
Compounds sterile drugs from bulkYes
FDA warning letters on GLP-1 drugs0

What did FDA’s investigators observe?

The Form 483 from the inspection of 12/19/2025 lists 10 observations. We sorted them by what each one is about, from the words of its opening sentence; the full wording is in FDA’s document.2

What the observation is aboutObservations
Testing and release of batches4
Equipment and facilities1
Sterility and aseptic processing1
Labeling and records1

FDA’s scan of the form is an image with a text layer; we do not quote it here because the text layer misreads some letters. Read the original on fda.gov.

Has this facility recalled any drugs?

FDA’s enforcement reports list 20 recalled products from this facility, from January 26, 2026 to January 26, 2026: 20 in Class II. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3

StartedClassProductReason
2026-01-26IITestosteronePresence of Foreign substance - potential presence of metal particulate matter
2026-01-26IITestosteronePresence of Foreign substance - potential presence of metal particulate matter
2026-01-26IITestosteronePresence of Foreign substance - potential presence of metal particulate matter
2026-01-26IIESTRADIOLPresence of Foreign substance - potential presence of metal particulate matter
2026-01-26IITestosteronePresence of Foreign substance - potential presence of metal particulate matter
2026-01-26IIESTRADIOLPresence of Foreign substance - potential presence of metal particulate matter
2026-01-26IITestosterone 200mgPresence of Foreign substance - potential presence of metal particulate matter
2026-01-26IIESTRADIOLPresence of Foreign substance - potential presence of metal particulate matter

The table shows 8 of the 20 recalls; the rest are in FDA’s enforcement reports.

Is the pharmacy behind my prescription on FDA’s list?

Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.

Pharmacy check100 facilities
Registered 503B—
With a Form 483—

Where are the registered outsourcing facilities?

2 of the 100 facilities on FDA’s list are in Alabama. The chart counts them by state; choose a view to see which ones FDA has inspected.

Facilities by stateFDA list, November 17, 2026
Show
Facilities—
Top state—

Which other facilities are in the same state?

What does it mean that a pharmacy is a 503B outsourcing facility?

An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1

A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.

Sources

  1. FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
  2. FDA. Form FDA 483, inspection of F.H. Investments, Inc., 12/05/2025 to 12/19/2025. fda.gov
  3. FDA. Drug recall enforcement reports for F.H. Investments, Inc., read through openFDA on November 20, 2026. open.fda.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider